Low serum concentrations of insulin-like growth factor-I in children with active Crohn disease - Effect of enteral nutritional support and glutamine supplementation

被引:22
作者
Akobeng, AK
Clayton, PE
Miller, V
Hall, CM
Thomas, AG
机构
[1] Cent Manchester Univ Hosp, Dept Paediat Gastroenterol, Manchester, Lancs, England
[2] Cent Manchester Univ Hosp, Dept Paediat Endocrinol, Manchester, Lancs, England
[3] Manchester Childrens Univ Hosp, Dept Paediat Endocrinol, Manchester, Lancs, England
[4] Manchester Childrens Univ Hosp, Dept Paediat Gastroenterol, Manchester, Lancs, England
关键词
children; Crohn disease; IGF-1; insulin-like growth factor I;
D O I
10.1080/003655202762671521
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Impaired growth is a frequent problem in childhood Crohn disease. Low serum concentrations of insulin-like growth factor-I (IGF-I), an important marker of nutritional status and linear growth, have been described in children with Crohn disease. This study tested the hypotheses that enteral nutritional support and glutamine supplementation would be associated with improvements in serum IGF-I levels in children with Crohn disease. Methods: In a double-blind randomized controlled study, 15 children with active Crohn disease (8 boys, 7 girls; mean age 11.3 years, range 6.8-15.7) were assigned to receive a 4-week course of either a standard low glutamine polymeric diet (4% of amino acid content) (Group S, n = 8) or an isocaloric, isonitrogenous, glutamine-enriched polymeric diet (42% of amino acid content) (Group G, n = 7). Serum IGF-I was measured by a radioimmunoassay method at 0 and 4 weeks and converted to standard deviation scores (SDS). Weight SDS, height SDS, weight-for-height, height-forage, mid-arm circumference (MAC), serum albumin, platelet count, orosomucoid and the paediatric Crohn disease activity index (PCDAI) were also measured at 0 and 4 weeks. Results: IGF-I SDS were significantly depressed in all the children at the start of the study (below -2 SDS) and remained so after 4 weeks of enteral nutritional support. Within each group, there was no significant change in IGF-I SDS (P = 0.306 for Group S and P = 0.903 for Group G). Nor was there any significant difference between the two groups when changes in IGF-I SDS over the 4-week period were compared (P = 0.568), although the proportion of patients experiencing an increase in IGF-I levels was greater in Group S (7 of 8 (87%) versus 2 of 7 (28%); P = 0.040). Weight SDS (P = 0.002), weight-for-height (P = 0.001) and mid-arm circumference (P = 0.001) increased significantly in Group S but the increases in Group G were not statistically significant. No significant correlation was found between changes in IGF-I SDS and changes in the following parameters: weight SDS (r = 0.170; P = 0.545), height SDS (r = -0.240; P = 0.389), weight-for-height (r = 0.261; P = 0.348), PCDAI (r = -0.156; P = 0.579) or orosomucoid (r = 0.173; P = 0.537). There was a significant negative correlation between changes in PCDAI and changes in weight SDS (r = -0.79; P < 0.001), and serum albumin (r = -0.76; P = 0.001) and a positive correlation between changes in PCDAI and changes in platelet count (r = 0.69; P = 0.004). Conclusions: Serum IGF-I SD scores were greatly diminished in children with active Crohn disease and showed no significant improvements after 4 weeks of nutritional support. Glutamine supplementation was not associated with any significant alterations in serum IGF-I.
引用
收藏
页码:1422 / 1427
页数:6
相关论文
共 33 条
[1]   Double-blind randomized controlled trial of glutamine-enriched polymeric diet in the treatment of active Crohn's disease [J].
Akobeng, AK ;
Miller, V ;
Stanton, J ;
Elbadri, AM ;
Thomas, AG .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2000, 30 (01) :78-84
[2]   Responsiveness of IGF-I and IGFBP-3 to therapeutic intervention in children and adolescents with Crohn's disease [J].
Beattie, RM ;
Camacho-Hübner, C ;
Wacharasindhu, S ;
Cotterill, AM ;
Walker-Smith, JA ;
Savage, MO .
CLINICAL ENDOCRINOLOGY, 1998, 49 (04) :483-489
[3]  
BOOTH IW, 1991, ACTA PAEDIATR SCAND, P91
[4]   Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I - A model for stunted growth in children with chronic inflammation [J].
DeBenedetti, F ;
Alonzi, T ;
Moretta, A ;
Lazzaro, D ;
Costa, P ;
Poli, V ;
Martini, A ;
Ciliberto, G ;
Fattori, E .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (04) :643-650
[5]  
*DEP HLTH, 1991, REP HLTH SOC SUBJ DI, P41
[6]   MODULATION OF INFLAMMATION-INDUCED CHANGES IN INSULIN-LIKE GROWTH-FACTOR (IGF)-I AND IGF BINDING PROTEIN-1 BY ANTI-TNF ANTIBODY [J].
FAN, J ;
LI, YH ;
BAGBY, GJ ;
LANG, CH .
SHOCK, 1995, 4 (01) :21-26
[7]   Nutritional factors and thalassaemia major [J].
Fuchs, GJ ;
Tienboon, P ;
Linpisarn, S ;
Nimsakul, S ;
Leelapat, P ;
Tovanabutra, S ;
Tubtong, V ;
DeWier, M ;
Suskind, RM .
ARCHIVES OF DISEASE IN CHILDHOOD, 1996, 74 (03) :224-227
[8]   Urinary IGF and IGF binding protein-3 in children with disordered growth [J].
Gill, MS ;
Whatmore, AJ ;
Tillman, V ;
White, A ;
Addison, GM ;
Price, DA ;
Clayton, PE .
CLINICAL ENDOCRINOLOGY, 1997, 46 (04) :483-492
[9]  
Hall CM, 1999, CLIN ENDOCRINOL, V50, P611
[10]  
Hickson RC, 1997, P SOC EXP BIOL MED, V216, P65